Metabolic syndrome predicts cardiovascular and all-cause adverse outcomes in patients with chronic inflammatory

Zhuoran Li1, Tingting Zou2, Yadong Li3

  • 1Shanxi Medical University, Taiyuan, 030001, China.

Clinical Rheumatology
|April 20, 2026
PubMed

Insights

Metabolic syndrome (MetS) significantly increases cardiovascular and all-cause risks in patients with chronic inflammatory arthritis (CIA). Each additional MetS component further elevates cardiovascular risk, highlighting the importance of managing MetS in this population.

Area of Science:

  • Rheumatology
  • Cardiology
  • Metabolic Diseases

Background:

  • Chronic inflammatory arthritis (CIA) is linked to higher cardiovascular risk.
  • Metabolic syndrome (MetS) is common in CIA patients and may worsen outcomes.

Purpose of the Study:

  • To determine if MetS independently predicts adverse cardiovascular and all-cause events in CIA patients.
  • To assess the relationship between the number of MetS components and patient prognosis.

Main Methods:

  • Prospective observational study of 811 CIA patients.
  • Propensity score matching (PSM) used to balance groups.
  • Cox regression and Kaplan-Meier analyses for outcome evaluation.

Main Results:

  • MetS was present in 35% of patients.
  • Patients with MetS had significantly higher rates of cardiovascular (18.4% vs 7.7%) and all-cause events (37.8% vs 19.9%).
  • MetS independently predicted cardiovascular (aHR=4.12) and all-cause outcomes (aHR=2.81). Each additional MetS component increased cardiovascular risk by 1.68-fold.

Conclusions:

  • MetS is an independent risk factor for adverse cardiovascular and all-cause outcomes in CIA patients.
  • A dose-response relationship exists: more MetS components lead to higher cardiovascular risk.
Abstract

Related Concept Videos

Coronary Artery Disease I: Introduction01:30

Coronary Artery Disease I: Introduction

Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...
1.8K
Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies01:22

Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies

The key clinical manifestations of Rheumatic heart disease (RHD) include several distinct cardiac symptoms.Carditis, a hallmark of acute rheumatic fever, involves inflammation of the heart's endocardium, myocardium, and pericardium. Chronic RHD often results from recurrent episodes of carditis. Its symptoms include the following:Murmurs are caused by valvular damage, especially to the mitral and aortic valves. Mitral stenosis or regurgitation is common, with characteristic heart murmurs...
1.2K
The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
10.0K
Atherosclerosis II: Clinical Manifestations and Diagnostic Tests01:27

Atherosclerosis II: Clinical Manifestations and Diagnostic Tests

Atherosclerosis is a progressive disorder that leads to the thickening and narrowing of arterial walls due to plaque buildup. This condition can cause various symptoms depending on the arteries affected:Coronary Artery Disease (CAD): This condition affects the coronary arteries and may lead to chest pain (angina), shortness of breath (dyspnea), heart attacks, and other heart disease symptoms.Cerebrovascular Disease: This affects blood flow to the brain, causing transient ischemic attacks (TIAs)...
802
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
604
Psychoneuroimmunology: Cardiovascular Disease01:27

Psychoneuroimmunology: Cardiovascular Disease

Psychoneuroimmunology (PNI) is a multidisciplinary field that examines how psychological factors, particularly stress, interact with the immune system and impact physical health. Research in PNI has shown that chronic or traumatic stress can disrupt both the hypothalamic-pituitary-adrenal axis and the sympathetic nervous system. These disruptions contribute to serious health conditions, including cardiovascular diseases.
A key area of focus in PNI is the relationship between stress and coronary...
746